NCT07439211 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07439211
Title	GAVEL: A Clinical Trial With Azacitidine, Venetoclax and Eganelisib (PI3K Gamma Inhibitor) in Acute Myeloid Leukemia (GAVEL)
Acronym	GAVEL
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Jacqueline Garcia, MD
Indications	acute myeloid leukemia
Therapies	Azacitidine + Eganelisib + Venetoclax
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Brigham and Women's Hospital		Boston	Massachusetts	02115	United States	Details
Dana Farber Cancer Institute		Boston	Massachusetts	02115	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07439211Clinical Trial Detail